Roivant Sciences Ltd. officer and director Mayukh Sukhatme filed an amended Form 144/A on November 10, 2026, notifying the SEC of a proposed sale of 173,725 shares of common stock pursuant to a mandatory sell-to-cover arrangement tied to equity award vesting.

Key Highlights

  • Proposed sale: 173,725 shares of Roivant Sciences Ltd. common stock with an aggregate market value of $7,122,725.00, according to the filing.
  • Seller: Mayukh Sukhatme, identified in the filing as both an officer and a director of the issuer.
  • Source of shares: The shares were acquired on November 10, 2026, through Performance Stock Units issued by the issuer, with payment described as "Services Rendered."
  • Sell-to-cover arrangement: The filing states the shares are being sold "automatically pursuant to a mandatory, non-discretionary, sell-to-cover arrangement adopted by the Issuer for the purpose of satisfying tax withholding obligations incurred upon the vesting and settlement of equity awards."
  • Shares outstanding: 724,561,460 shares of common stock were reported outstanding at the time of the filing.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the executing broker.
  • Exchange: Securities are listed on NASDAQ:ROIV, as stated in the filing.

Sukhatme's November 2026 Sell-to-Cover Filing and Recent Sales History

According to the amended Form 144/A filed with the SEC on November 10, 2026, Mayukh Sukhatme, an officer and director of Roivant Sciences Ltd. (NASDAQ:ROIV), proposed to sell 173,725 shares of the company's common stock. The filing identifies the approximate date of sale as November 10, 2026. The shares carry a reported aggregate market value of $7,122,725.00. The amendment was filed to add remarks clarifying the nature of the transaction.

The filing's remarks section states verbatim that "The Shares covered by this Form 144 are being sold automatically pursuant to a mandatory, non-discretionary, sell-to-cover arrangement adopted by the Issuer for the purpose of satisfying tax withholding obligations incurred upon the vesting and settlement of equity awards." The shares were acquired the same day, November 10, 2026, via Performance Stock Units granted by the issuer.

The filing also discloses sales made by Sukhatme during the prior three months. Those transactions, all in common stock, include: 284,707 shares sold on August 17, 2026, with gross proceeds of $10,320,571.81; 243,177 shares on August 14, 2026, for $8,809,767.72; 172,899 shares on August 19, 2026, for $6,426,356.82; 144,756 shares on August 21, 2026, for $5,280,004.05; 136,942 shares on August 18, 2026, for $5,029,208.64; and 17,519 shares on August 20, 2026, for $653,407.89. These prior-period figures are reported as required disclosures under Rule 144 and are attributed to Sukhatme at 7th Floor, 50 Broadway, London, SW1H 0DB.

What Was Disclosed

Mayukh Sukhatme, an officer and director of Roivant Sciences Ltd., filed an amended Form 144/A disclosing a proposed sale of 173,725 common shares valued at $7,122,725.00, acquired via Performance Stock Units and to be sold through a mandatory issuer-adopted sell-to-cover arrangement for tax withholding purposes.